Saturday, 20 April 2024
Protalix BioTherapeutics Inc.
00:26 | 17/3/18
Post Analyst
Protalix BioTherapeutics, Inc. is maintained at an average outperform rating by 4 stock analysts, and there are at least 3.65% of shares outstanding that are currently legally short sold.
more»
23:30 | 15/3/18
Post Analyst
Protalix BioTherapeutics, Inc. (NYSE:PLX) marched up 20.83% compared to a 52-week low price of $0.48. The shares were last seen trading -9.56% lower, taking the closing price at $0.58 on 03/14/2018.
more»
03:48 | 15/3/18
Seeking Alpha
Protalix announced the results of their phase 2 open label trial of OPRX-106 for the treatment of Ulcerative Colitis on March 13.
more»
03:37 | 15/3/18
Stocks Gallery
In latest trading activity; Protalix BioTherapeutics, Inc. (PLX) snatched the consideration from Investors, when its current damaging picture was seen that is promoting bad performance.
more»
01:00 | 15/3/18
StockNewsGazette
The shares of Protalix BioTherapeutics, Inc. have decreased by more than -3.01% this year alone. The shares recently went down by -4.28% or -$0.03 and now trades at $0.64.
more»
03:03 | 14/3/18
Post Analyst
Protalix BioTherapeutics, Inc. (NYSE:PLX) current P/S is an impressive 5.11. The overall Biotechnology group has an average P/S ratio of 150.71, which is significantly worse than the sector's 9.05.
more»
CARMIEL, Israel, March 13, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today, positive results from the Company's phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis.
more»
04:00 | 9/3/18
Frisco Fastball
More notable recent Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) news were published by: Globenewswire.com which released: “Protalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global …” on September 05, 2017, also Seekingalpha ...
more»
04:45 | 8/3/18
Dispatch Tribunal
A hedge fund recently bought a new stake in Protalix Biotherapeutics stock. Opaleye Management Inc. purchased a new position in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) during the fourth quarter, according to the company in its most ...
more»
01:22 | 7/3/18
GlobeNewswire
Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner.
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |